Related Experiment Video

Updated: May 21, 2026

Microbiological Rapid On-Site Evaluation for Pulmonary Infectious Diseases
03:22

Microbiological Rapid On-Site Evaluation for Pulmonary Infectious Diseases

Published on: March 1, 2024

[Pneumocystis jirovecii pneumonia in HIV-infected patients]

N De Castro1, A Scemla, S Gallien

  • 1Service de maladies infectieuses et tropicales, hôpital Saint-Louis, AP-HP, 75010 Paris, France. nathalie.de-castro@sls.aphp.fr

Revue Des Maladies Respiratoires
|June 30, 2012
PubMed
Abstract

Insights

Pneumocystis jirovecii pneumonia remains a significant AIDS-related infection in France. Early antiretroviral therapy and HIV testing are expected to further decrease its incidence.

Area of Science:

  • Infectious Diseases
  • Immunology
  • Public Health

Background:

  • Pneumocystis jirovecii pneumonia (PJP) persists as a major AIDS-related infection in France, despite advances in antiretroviral therapy.
  • Diagnosis is typically straightforward in HIV-infected patients, with high-dose trimethoprim-sulfamethoxazole and steroids for severe cases significantly reducing mortality.
  • Prophylaxis is crucial for highly immunosuppressed patients (CD4 < 200/μL) with uncontrolled HIV viremia.

Purpose of the Study:

  • To review the current status of Pneumocystis jirovecii pneumonia in France.
  • To discuss diagnostic and treatment strategies for PJP in HIV-infected patients.
  • To evaluate the impact of evolving HIV management guidelines on PJP incidence.

Main Methods:

  • Review of clinical, radiological, and microbiological diagnostic approaches for PJP.
  • Analysis of treatment outcomes with trimethoprim-sulfamethoxazole and alternative regimens.
  • Discussion of prophylactic strategies and their role in preventing PJP.
  • Consideration of PCR-based diagnostics and the significance of P. jirovecii colonization.

Main Results:

  • High-dose trimethoprim-sulfamethoxazole is the preferred treatment, leading to reduced mortality.
  • Prophylactic treatment is mandatory for specific patient groups.
  • The clinical utility of PCR-based diagnosis for PJP in HIV patients remains under debate.
  • Optimal alternative treatment regimens for PJP failure or intolerance are not well-defined.

Conclusions:

  • The frequency of PJP is anticipated to decrease further in France due to universal HIV testing and early antiretroviral therapy initiation.
  • Further research is needed to clarify the role of PCR diagnostics and define alternative treatment options for PJP.
  • Ongoing vigilance and adherence to prophylactic guidelines are essential for managing PJP in the evolving landscape of HIV care.

More Related Videos

Processing of Bronchoalveolar Lavage Fluid and Matched Blood for Alveolar Macrophage and CD4+ T-cell Immunophenotyping and HIV Reservoir Assessment07:21

Processing of Bronchoalveolar Lavage Fluid and Matched Blood for Alveolar Macrophage and CD4+ T-cell Immunophenotyping and HIV Reservoir Assessment

Published on: June 23, 2019

Visualization of Pseudomonas aeruginosa within the Sputum of Cystic Fibrosis Patients07:25

Visualization of Pseudomonas aeruginosa within the Sputum of Cystic Fibrosis Patients

Published on: July 16, 2020

Related Concept Videos

Pneumonia II: Pathophysiology01:29

Pneumonia II: Pathophysiology

The pathophysiology of pneumonia involves the following steps:
Pneumonia I: Introduction01:30

Pneumonia I: Introduction

Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Pneumonia I: Introduction01:29

Pneumonia I: Introduction

Pneumonia is an infection of the lower respiratory tract that leads to inflammation of the lung parenchyma, often resulting in the accumulation of inflammatory exudate in the alveoli and airways. Unlike the watery, low-protein fluid exudate in pulmonary edema, the exudate in this case is a thick fluid rich in immune cells, proteins, and debris produced during infection and inflammation.This impairs gas exchange and can lead to consolidation of lung tissue. The infection may be caused by a...
Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Pneumonia V: Nursing management and Prevention01:30

Pneumonia V: Nursing management and Prevention

Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed.